Trial Profile
Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2-Drug Regimen Juluca, a Onepill-Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir/rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms JUNGLE
- Sponsors ViiV Healthcare
- 24 Aug 2023 Status changed from recruiting to completed.
- 12 Jan 2023 Planned End Date changed from 31 Jul 2022 to 30 May 2023.
- 12 Jan 2023 Planned primary completion date changed from 31 Jul 2022 to 14 May 2023.